 PRINCETON, N.J., March 12, 2021 GLOBE NEWSWIRE -- Advaxis, Inc. Nasdaq: ADXS, a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and Precision for Medicine, a specialized services company supporting next generation approaches to drug development and commercialization, today announce that they will present data on a the development of a novel flow immunophenotyping assay to accurately evaluate total PD-1 expression as a pharmacodynamic biomarker during PD-1 blockade treatment with pembrolizumab and b the correlation of changes in T cell populations with the clinical activity observed in the ongoing ADXS-503 clinical trial, in a poster presentation at the American Association for Cancer Research AACR Annual Meeting 2021, taking place virtually from April 10-15, 2021. 